SCHEMBL3637175

SCHEMBL3637175

COc1ccccc1N1CCN(C(=O)C2CC(N(C)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CN2Cc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
HTR7 P34969 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 2/20 0.42
TACR3 P29371 3/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2822151 1.00 NPC1 (0.51) NPC1HTR7GAAKMT2AALDH1A1
SCHEMBL2819947 0.94 NPC1 (0.49) NPC1HTR7GAAKMT2AALDH1A1
SCHEMBL2820035 0.90 TACR3 (0.44) GAAKMT2AALDH1A1TACR3POLB
SCHEMBL3641111 0.90 TACR3 (0.44) GAAKMT2AALDH1A1TACR3POLB
SCHEMBL2819005 0.88 CHRM4 (0.43) NPC1TACR3
SCHEMBL2817106 0.85 CHRM4 (0.47) KMT2AALDH1A1POLBMEN1SMN1; SMN2
SCHEMBL3638622 0.85 CHRM4 (0.47) KMT2AALDH1A1POLBMEN1SMN1; SMN2
SCHEMBL2821138 0.85 CACNA1G (0.45) NPC1GAAKMT2AALDH1A1TACR3
SCHEMBL2822473 0.84 KMT2A (0.41) KMT2AALDH1A1TACR3POLBMEN1
SCHEMBL3641058 0.84 KMT2A (0.41) KMT2AALDH1A1TACR3POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed